256 320
Table 1 (
Continued
)
Study
Study design Period Population
Pt Nb
Mean/
median*
age (yr)
Mean/median*
PSA (ng/ml)
Mean/
median*
prostate
volume (cm
3
)
Magnetic
field
strength
MR pulse
sequences
Endorectal
coil
MR score
Definition of
positive MRI
Reference standard
Vinet (2013)
[57]
Prospective 2009–2011 FB
69
NR
5.2* (3.2–28)
NR
1.5 T
(35 pts) &
3 T (34 pts)
T2WI/DWI/DCEI
No
1–5 scale
(Likert)
3
12-core TRUS SBx + TBx
Numao (2013)
[38]
Prospective 2006–2010 FB
351
65* (59–70)
6.3* (4.9–9.1)
32* (24–42)
1.5 T
T2WI/DWI/DCEI
(no DCEI in 42 pts)
No
1–5 scale
(Likert)
3
3D 26-core (12 TRUS
SBx + 14 TPBx – 203 pts);
3D 14-core
(6 TRUS SBx + 8 TPBx
– 102 pts);
TPBx 14 core (46 pts)
Belas (2012)
[14]
Prospective 2010–2011 FB
71
66* (47–76)
7* (4–10)
45* (15–150)
1.5 T
T2WI/DWI/DCEI
No
TZ: 0–4 scale
PZ: 0–10 scale
TZ:
>
2
PZ:
>
6
12-core TRUS SBx + TBx
Ibrahiem (2012)
[26]Prospective 2008–2009 FB
100
65.03 (7.13)
26.3 (24.2)
60.09 (28.7)
1.5 T
T2WI/DWI
No
NR
In house
12-core TRUS SBX
Sciarra (2012)
[51]
Prospective 2008–2011 PNB
84
64.09 (46–76)
7.07 (4.2–15.5)
NR
3 T
T2WI/DWI/
DCEI/MRSI
Yes
NR
NR
10-core TRUS Bx + TBx
Portalez (2012)
[45]
Prospective 2011
PNB
129
64.7 (47–79)
9.6 (2.7–40)
51.1 (12–192)
1.5 T
T2WI/DWI/DCEI
Mixed 1–5 scale
(Likert)
PI-RADS
Likert 3
PI-RADS 9
10–12-core TRUS
SBx + TBx
Watanabe (2012)
[59]Prospective 2004–2008 NR
1448
72 (7.5)
NR
NR
1.5 T
T2WI/DWI
No
NR
ADC value
1.35
10
3
mm
2
/s
8-core TRUS SBx + TBx
Tamada (2011)
[54]Retrospective 2006–2009 NR
50
70 (40–84)
6.84* (4.06–9.94)
NR
1.5 T
T2WI/DWI/DCEI
No
NR
In house
12-core TRUS SBx
Choi (2011)
[18]NR
2009–2010 NR
51
67.16 (56–90)
14.16 (1.02–38.9)
42.98
(13.8–77.3)
3 T
T2WI/DWI
NR
NR
NR
10–12-core TRUS
SBx + TBx
Iwazawa (2011)
[28]
Retrospective 2008–2009 NR
178
68.8 (41–86)
20.51 (4.04–568.5) NR
1.5 T
T2WI/DWI/DCEI
NR
1–4 scale
(Likert)
NR
10–12-core TRUS SBx
(TBx included in
SBx chart)
Rouse (2011)
[48]Prospective 2005–2007 PNB
114
63.6 (41–83)
13.4 (0–228)
NR
1.5 T
T2WI/DWI/DCEI
NR
1–5 scale
(Likert)
3
TRUS SBx
Haffner (2011)
[23]Prospective 2005–2009 FB
555
64* (47–83)
6.75* (0.18–100)
46* (15–200)
1.5 T
T2WI/DCEI
No
1–5 scale
(Likert)
3
10-core TRUS SBx + TBx
Panebianco (2010)
[40]Prospective 2007–2009 PNB
150
61.2 (46–78)
9.42 (3.91)
41.17 (7.47)
1.5 T
T2WI/DCEI/MRSI
Yes
NR
In house
10-core TRUS SBx
(TBx included in
SBx chart)
Roy (2010)
[49]Not specified 2011–2009 FB (53%) &
PNB (47%)
103
63 (52–78)
7*
NR
3 T
T2WI/DWI/DCEI
Yes
NR
NR
8-core TRUS SBx + TBx
Testa (2010)
[55]Not specified 2007
PNB
54
63.9 (52–76)
11.4 (3–42)
59.3 (30–150)
1.5 T
T2WI/MRSI
Yes
1–3 scale
(Likert)
2
12-core TRUS SBx + TBx
Sciarra (2010)
[52]
Prospective 2007–2009 PNB
110
63.5 (49–74)
NR
NR
1.5 T
T2WI/DCEI/MRSI
Yes
NR
In house
10-core TRUS SBx + TBx
Kitajima (2010)
[31]
Prospective 2008–2009 NR
53
69* (56–84)
11.1* (4.2–112.1)
NR
3 T
T2WI/DWI/DCEI
No
1–5 scale
(Likert)
3
20-core TPBx
Labanaris (2010)
[35]
Prospective 2004–2008 PNB
260
NR
NR
NR
1 T
T2WI/DWI/DCEI
Yes
Dichotomous In house
18-core TRUS SBx
Kumar (2009)
[32]NR
NR
NR
61
65.3 (9.3)
16.5 (0.21–155)
NR
1.5 T
T2WI/MRSI
Yes
NR
(Cit/(Cho + Cr)
1.2
TRUS Bx
Schmuecking
(2009)
[50]NR
NR
FB & PNB
67
68
11.5
NR
1.5 T
T2WI/DCEI
No
NR
NR
20-core Bx
Cheikh (2009)
[17]
Retrospective 2005–2008 PNB
93
63.2 (52–74)
9.63 (1.6–40)
NR
1.5 T
T2WI/DCEI
No
Dichotomous In house
12-core TRUS SBx + TBx
Cirillo (2008)
[19]Prospective 2004–2006 PNB
54
65.5 (5.2)
10.8 (7.5)
NR
1.5 T
T2WI/MRSI
Yes
Dichotomous In house
10-core TRUS SBx + TBx
Kumar (2007)
[33]Prospective 2003–2005 NR
83
NR
NR
NR
1.5 T
T2WI/MRSI
Yes
NR
NR
12-core TRUS SBx + TBx
Squillaci (2005)
[53]
Prospective 2004–2005 NR
65
NR
NR
NR
1.5 T
T2WI/DCEI/MRSI
No
1–3 scale
(Likert)
2
10-core TRUS SBx + TBx
Hara (2005)
[24]
Prospective 2003–2004 FB
90
67.2 (NR)
NR
NR
1.5 T
T2WI/DCEI
No
1–3 scale
(Likert)
2
= 3
14-core TRUS SBx
FB = first biopsy; IQR = interquartile range; PNB = previous negative biopsy; Pt = patient; Nb = number; MR = magnetic resonance; MRI magnetic resonance imaging; T2WI = T2-weighted imaging; DWI = diffusion-
weighted imaging; DCEI = dynamic contrast-enhanced imaging; MRSI = magnetic resonance spectroscopic imaging; NR = not reported; Bx = biopsy; TRUS SBx = transrectal ultrasound-guided standard biopsy;
TPBx = transperineal template biopsy; TBx = targeted biopsy; PCa = prostate cancer; PI-RADS = Prostate Imaging Reporting Data System; PSA = prostate-specific antigen; PZ = peripheral zone; TZ = transition zone.
Figures between parenthesis correspond to standard deviations; intervals between brackets correspond to full ranges or interquartile ranges when specified (IQR). The asterisk sign indicates median value (as opposed to
mean value).
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 2 5 0 – 2 6 6
256